Trepulmix

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

下载 资料单张 (PIL)
23-01-2023
下载 产品特点 (SPC)
23-01-2023
下载 公众评估报告 (PAR)
21-09-2023

有效成分:

Treprostinil sodium

可用日期:

SciPharm Sàrl

ATC代码:

B01AC21

INN(国际名称):

treprostinil

治疗组:

Antithrombotic agents

治疗领域:

Hypertension, Pulmonary

疗效迹象:

Treatment of adult patients with WHO Functional Class (FC) III or IV and:inoperable chronic thromboembolic pulmonary hypertension (CTEPH), orpersistent or recurrent CTEPH after surgical treatmentto improve exercise capacity.

產品總結:

Revision: 4

授权状态:

Authorised

授权日期:

2020-04-03

资料单张

                                31
B.
PACKAGE LEAFLET
32
PACKAGE LEAFLET: INFORMATION FOR THE USER
TREPULMIX 1 MG/ML SOLUTION FOR INFUSION
TREPULMIX 2.5 MG/ML SOLUTION FOR INFUSION
TREPULMIX 5 MG/ML SOLUTION FOR INFUSION
TREPULMIX 10 MG/ML SOLUTION FOR INFUSION
treprostinil
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Trepulmix is and what it is used for
2.
What you need to know before you use Trepulmix
3.
How to use Trepulmix
4.
Possible side effects
5.
How to store Trepulmix
6.
Contents of the pack and other information
1.
WHAT TREPULMIX IS AND WHAT IT IS USED FOR
WHAT TREPULMIX IS
The active ingredient of Trepulmix is treprostinil.
Treprostinil belongs to a group of medicines which work in a similar
way to the naturally occurring
prostacyclins. Prostacyclins are hormone-like substances which reduce
blood pressure by relaxing
blood vessels, causing them to widen, which allows the blood to flow
more easily. Prostacyclins can
also have an influence in preventing blood from clotting.
WHAT TREPULMIX IS USED TO TREAT
Trepulmix is used for the treatment of adult patients with inoperable
chronic thromboembolic
pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after
surgical treatment (severity
classified WHO Functional Class (FC) III or IV), to improve exercise
capacity and symptoms of the
disease. Chronic thromboembolic pulmonary hypertension is a condition
where your blood pressure is
too high in the blood vessels between the heart and the lungs causing
shortness of breath, dizziness,
tiredness, fainting, palpitations or abnor
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Trepulmix 1 mg/ml solution for infusion
Trepulmix 2.5 mg/ml solution for infusion
Trepulmix 5 mg/ml solution for infusion
Trepulmix 10 mg/ml solution for infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Trepulmix 1 mg/ml solution for infusion:
One ml of solution contains 1 mg treprostinil (as sodium salt).
Each 10 ml vial of solution contains 10 mg treprostinil (as sodium
salt).
_Excipients with known effect _
Each 10 ml vial contains 36.8 mg (1.60 mmol) sodium.
Trepulmix 2.5 mg/ml solution for infusion:
One ml of solution contains 2.5 mg treprostinil (as sodium salt).
Each 10 ml vial of solution contains 25 mg treprostinil (as sodium
salt).
_Excipients with known effect _
Each 10 ml vial contains 37.3 mg (1.62 mmol) sodium.
Trepulmix 5 mg/ml solution for infusion:
One ml of solution contains 5 mg treprostinil (as sodium salt).
Each 10 ml vial of solution contains 50 mg treprostinil (as sodium
salt).
_Excipients with known effect _
Each 10 ml vial contains 39.1 mg (1.70 mmol) sodium.
Trepulmix 10 mg/ml solution for infusion:
One ml of solution contains 10 mg treprostinil (as sodium salt).
Each 10 ml vial of solution contains 100 mg treprostinil (as sodium
salt).
_Excipients with known effect _
Each 10 ml vial contains 37.4 mg (1.63 mmol) sodium.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for infusion.
Clear colourless to slightly yellow solution, free from visible
particles with a pH of 6.0 – 7.2 and an
osmolality between 253 and 284 mOsm/kg.
3
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Trepulmix is indicated for the treatment of adult patients with WHO
Functional Class (FC) III or IV
and:
-
inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or
-
persistent or recurrent CTEPH after surgical treatment to improve
exercise capacity.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Treatment with Trepulmix should be initiated and monitored only by
clinicians experienced in the

                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 23-01-2023
产品特点 产品特点 保加利亚文 23-01-2023
公众评估报告 公众评估报告 保加利亚文 21-09-2023
资料单张 资料单张 西班牙文 23-01-2023
产品特点 产品特点 西班牙文 23-01-2023
公众评估报告 公众评估报告 西班牙文 21-09-2023
资料单张 资料单张 捷克文 23-01-2023
产品特点 产品特点 捷克文 23-01-2023
公众评估报告 公众评估报告 捷克文 21-09-2023
资料单张 资料单张 丹麦文 23-01-2023
产品特点 产品特点 丹麦文 23-01-2023
公众评估报告 公众评估报告 丹麦文 21-09-2023
资料单张 资料单张 德文 23-01-2023
产品特点 产品特点 德文 23-01-2023
公众评估报告 公众评估报告 德文 21-09-2023
资料单张 资料单张 爱沙尼亚文 23-01-2023
产品特点 产品特点 爱沙尼亚文 23-01-2023
公众评估报告 公众评估报告 爱沙尼亚文 21-09-2023
资料单张 资料单张 希腊文 23-01-2023
产品特点 产品特点 希腊文 23-01-2023
公众评估报告 公众评估报告 希腊文 21-09-2023
资料单张 资料单张 法文 23-01-2023
产品特点 产品特点 法文 23-01-2023
公众评估报告 公众评估报告 法文 21-09-2023
资料单张 资料单张 意大利文 23-01-2023
产品特点 产品特点 意大利文 23-01-2023
公众评估报告 公众评估报告 意大利文 21-09-2023
资料单张 资料单张 拉脱维亚文 23-01-2023
产品特点 产品特点 拉脱维亚文 23-01-2023
公众评估报告 公众评估报告 拉脱维亚文 21-09-2023
资料单张 资料单张 立陶宛文 23-01-2023
产品特点 产品特点 立陶宛文 23-01-2023
公众评估报告 公众评估报告 立陶宛文 21-09-2023
资料单张 资料单张 匈牙利文 23-01-2023
产品特点 产品特点 匈牙利文 23-01-2023
公众评估报告 公众评估报告 匈牙利文 21-09-2023
资料单张 资料单张 马耳他文 23-01-2023
产品特点 产品特点 马耳他文 23-01-2023
公众评估报告 公众评估报告 马耳他文 21-09-2023
资料单张 资料单张 荷兰文 23-01-2023
产品特点 产品特点 荷兰文 23-01-2023
公众评估报告 公众评估报告 荷兰文 21-09-2023
资料单张 资料单张 波兰文 23-01-2023
产品特点 产品特点 波兰文 23-01-2023
公众评估报告 公众评估报告 波兰文 21-09-2023
资料单张 资料单张 葡萄牙文 23-01-2023
产品特点 产品特点 葡萄牙文 23-01-2023
公众评估报告 公众评估报告 葡萄牙文 21-09-2023
资料单张 资料单张 罗马尼亚文 23-01-2023
产品特点 产品特点 罗马尼亚文 23-01-2023
公众评估报告 公众评估报告 罗马尼亚文 21-09-2023
资料单张 资料单张 斯洛伐克文 23-01-2023
产品特点 产品特点 斯洛伐克文 23-01-2023
公众评估报告 公众评估报告 斯洛伐克文 21-09-2023
资料单张 资料单张 斯洛文尼亚文 23-01-2023
产品特点 产品特点 斯洛文尼亚文 23-01-2023
公众评估报告 公众评估报告 斯洛文尼亚文 21-09-2023
资料单张 资料单张 芬兰文 23-01-2023
产品特点 产品特点 芬兰文 23-01-2023
公众评估报告 公众评估报告 芬兰文 21-09-2023
资料单张 资料单张 瑞典文 23-01-2023
产品特点 产品特点 瑞典文 23-01-2023
公众评估报告 公众评估报告 瑞典文 21-09-2023
资料单张 资料单张 挪威文 23-01-2023
产品特点 产品特点 挪威文 23-01-2023
资料单张 资料单张 冰岛文 23-01-2023
产品特点 产品特点 冰岛文 23-01-2023
资料单张 资料单张 克罗地亚文 23-01-2023
产品特点 产品特点 克罗地亚文 23-01-2023
公众评估报告 公众评估报告 克罗地亚文 21-09-2023

搜索与此产品相关的警报

查看文件历史